Zenas BioPharma, Inc. (ZBIO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US98937L1052
Zenas BioPharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 10.00 m USD |
| Operating income | -383.06 m USD |
| EBIT | -382.64 m USD |
| Net income | -377.74 m USD |
| Diluted EPS – continuing operations | -8.44 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
More stocks
- BIOLIFE SOLUTIONS INC (BLFS)
- Mineralys Therapeutics, Inc. (MLYS)
- AEHR TEST SYSTEMS (AEHR)
- Sparebank 1 Nord-Norge (NONG.OL)
- Bell Food Group AG (BELL.SW)
- Spectrum Brands Holdings, Inc. (SPB)
- Xianhe Co Ltd (603733.SS)
- FIBRA Macquarie México (FIBRAMQ12.MX)
- Hutchison Port Holdings Trust (NS8U.SI)
- Dime Commercial Bancshares, Inc. /NY/ (DCOM)
- Landis+Gyr Group AG (LAND.SW)
- Parex Resources Inc (PXT.TO)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.